Les domaines lucratifs de la santé : biologie, radiologie et audioprothèses au cœur des dépenses de la Sécu

For several years, the management of healthcare expenses remains at the heart of government and social security concerns. In 2025, the fields of medical biology, radiology, and hearing aids stand out particularly due to their economic weight and profitability, sparking debates and worries about the sustainability of financial flows. The health insurance reveals a pioneering study highlighting a significant growth in turnover and profits in these areas, with operational margins often exceeding 15%, well above the national average. This reality raises the issue of “economic rents” that Social Security is forced to finance, calling for stricter regulation and more equitable distribution of expenses. In this context, major groups like Bioscience, Radiology Plus, Auditech, and BioCare play a central role in restructuring the healthcare landscape, accompanied by technological players such as MedTech Solutions or Santech. The challenges are multiple: cost control, care efficiency, territorial equity, and prevention of financial misuse linked to the concentration and financialization of actors. Throughout this article, a detailed spotlight on these lucrative sectors and proposals aimed at ensuring the system’s sustainability.

Analysis of profit margins in medical biology: an alarming growth

Medical biology is a strategic sector within healthcare, involved in patient diagnosis and therapeutic monitoring. Since 2018, however, the operational profitability of laboratories has seen a notable increase, rising from 15% to nearly 24% in just a few years. These high margins inevitably result from a pricing structure set by Social Security that is often above their actual costs, raising questions about the economic and social management of the sector.

Within biology, the market concentration among the six main groups (Biogroup, Cerballiance, Inovie, Synlab, Eurofins, and Unilab) is a significant phenomenon. These entities now represent more than two-thirds of total revenue, consolidating significant economic power that primarily benefits their shareholders, including foreign investment funds. This concentration is also accompanied by an aggressive strategy of geographical expansion, with a race to multiply sites, less aligned with actual demographic needs than with purely economic logic.

• 📈 Constantly increasing operational profitability
• 🏢 Concentration around six major groups
• 🌍 Geographical expansion disconnected from real needs
• 💰 Profits captured largely by foreign funds
• ⚠️ Risks associated with excessive financialization of the sector

According to the report published by SécuSanté, this financialization also leads to fragility through over-reliance on debt. Reckless investors have driven some groups into delicate financial situations, threatening medium-term stability. Indeed, the pressure exerted by creditors, prioritizing financial returns, can result in a reduction in care quality and significant territorial imbalance.

Key Actor 🏥	Market Share (%) 📊	Operational Profitability (%) 💹	Type of Shareholders	Average Monthly Doctor Income (€) 💶
Biogroup	20%	24%	Foreign Funds
Cerballiance	18%	23%	Institutional Investors
Synlab	16%	22%	Private Equity
Eurofins	10%	21%	Foreign Funds
Unilab	6%	20%	Investment Funds
Inovie	9%	19%	Private, same family

The need for structural reform, discussed in several reports, particularly regarding the PLFSS 2025, aims to better regulate these dynamics to ensure a fair distribution of resources and a homogeneous quality of care across the territory. This approach requires balancing economic efficiency and social responsibility.

Radiology: a rapidly expanding sector but with controversial profitability

The radiology sector is among the most impacted by debates on healthcare costs and excessive profitability. With operational profitability increasing from 11% to 16% over five years, this field remains attractive for both professionals and investors. Radiology Plus and Radiant Health are among the key names dominating this complex market, combining medical expertise and technical innovations.

A notable phenomenon concerns the salary disparity among different specialists. According to a recent study by the Ministry of Health, the 5,000 outpatient radiologists in France earn an average net monthly salary of 17,725 euros, while nuclear medicine doctors and radiation oncologists exceed 23,000 and 34,000 euros respectively. These remunerations reinforce the sector’s attractiveness but raise calls for a review of tariff scales, highlighted by the health insurance on its official platform.

• ⚖️ Constantly increasing operational profitability
• 💼 Dominant presence of Radiology Plus and Radiant Health
• 💵 High salaries above the national average
• 🌆 Geographic concentration in major cities
• 🔄 Pressure for revising Social Security tariffs

The organization of territory in radiology shows a very uneven distribution of specialized clinics and centers, with a strong dominance in large urban areas. This imbalance poses a risk of “medical desertification” in rural and peripheral areas, exacerbating inequalities in access to care. The growth of private centers, driven more by economic strategies than actual needs, reinforces this issue.

Profession 🧑‍⚕️	Staff in France 🇫🇷	Average Net Monthly Salary (€) 💰	Main Groups 📌	Operational Profitability (%) 📈
Radiologists	5,000	17,725	Radiology Plus	16
Nuclear medicine physicians	375	23,600	Radiant Health	18
Radiation oncologists	420	34,790	Radiology Plus	27

The modernization of equipment and digitalization of practices by companies like MedTech Solutions contribute to this dynamic, while increasing costs. Tariff regulation by social security, criticized for its lack of adaptability, needs reevaluation to avoid exceeding budget caps set within the framework of the PLFSS, as discussed on biologiste365.fr.

Hearing aids: a thriving market under increased supervision

The hearing aid sector, driven by companies such as Auditech and Audiologie France, shows increasing profitability, rising from 11% to 16% in recent years. This growth is notably supported by demographic aging and increased awareness of hearing problems, amplifying demand and generating significant expenses for social security.

Several factors explain this worrying growth. A price often above the actual cost of devices, combined with sometimes aggressive commercial practices, fuels significant “rents” in this sector. Price segmentation, coupled with reimbursements heavily subsidized by social security, is particularly questioned. The need for tariff reform and better regulation is explicitly stated in available reports, notably through the latest senatorial report.

• 🎧 Market driven by demographic aging
• 💰 Prices above actual costs
• 🛡️ Heavy dependence on social security reimbursements
• ⚠️ Commercial practices under surveillance
• 🔄 Calls for tariff reform

Hearing care professionals hold a strategic position in the audiological supply chain. However, their significant profitability raises increased attention from control authorities to prevent excesses that could harm access equality, especially in rural or disadvantaged areas. The growth of innovative technologies by companies like Biomédical Innov or Santech helps modernize the sector while complicating cost management.

Key Company 🎯	Operational Profitability (%) 🚀	Main Hearing Aid Models	Dependency on Social Security Reimbursements (%)	Market Outlook
Auditech	16	High-end models	85%	Stable growth linked to aging
Audiologie France	15	Standard devices	82%	Ongoing technological innovation
Biomédical Innov	14	Connected solutions	80%	Gradual premiumization
Santech	13	Custom devices	78%	Market development in rural areas

Faced with these issues, a collective effort between institutions, professionals, and industries is necessary to balance supply and costs while ensuring optimal care quality for patients. Discussions on these themes are widely open within government bodies and specialized platforms such as Aide BTS Assurance.

Increasing financialization: impact on care quality and equitable access

The financialization of healthcare sectors, particularly visible in medical biology and radiology, poses a major challenge for public regulation. The growing influence of investment funds, often foreign, transforms these segments into lucrative markets sometimes at the expense of quality and accessibility of care. Recent developments highlight the need to balance profitability with social missions.

This dynamic results in:

• 💼 Predominance of financial logic over health objectives
• 📉 Increased cost pressures leading to drastic cuts
• 🌍 Unequal distribution of services across the national territory
• ⚠️ Fragilization of fragile structures under economic constraints
• 🤝 Call for coordinated recovery measures between public authorities and private actors

Financial optimization strategies, such as multiplying sites or consolidating actors, diverge from addressing real needs and contribute to deepening territorial inequalities. According to a detailed senatorial report available on le Quotidien du Médecin, this phenomenon carries the risk of exceeding budget caps but also of a potential crisis in care provision.

Element of Financialization 💸	Impact on Health ⚕️	Recommended Actions 🤔
Concentration of actors	Decreased local availability and reduced competition	Enhancing regulation and antitrust controls
Over-reliance on debt	Financial fragility and quality loss	Strict regulation of external financing
Aggressive tariff optimization	Overconsumption and excessive spending	Revising reimbursement scales

Regulatory and control measures, such as those outlined in the national strategy for the health sector, aim to curb these excesses to preserve fair, sustainable, and effective access to care, while promoting responsible innovation led by actors like BioCare or MedTech Solutions.

Territorial disparities: a challenge for equity in biology and radiology care

Geographical inequalities in the distribution of laboratories and radiology clinics are a major issue highlighted in recent reports. Concentration in urban areas favors easier access for populations in large metropolises, while rural and peripheral zones remain underserved.

This problem is observed according to several criteria:

• 🏙️ High density of actors in Île-de-France and major urban areas
• 🚜 Medical desertification in rural territories
• 📅 Insufficient efforts to develop infrastructure outside urban zones
• 🕒 Longer waiting times in some public hospitals
• 🔄 Concentration of equipment in private groups favoring profitable zones

Initiatives led by SécuSanté and Santech aim to invest in better allocation of resources, including support for mobile structures, telemedicine, and public-private partnerships to deploy quality diagnostics in isolated areas. These solutions are already recognized as essential levers to rebalance the offer.

Geographical Area 🗺️	Number of Laboratories / Clinics 🔬	Average Access to Care (%)	Average Waiting Time (days) ⏳	Ongoing Initiatives 💡
Ile-de-France	2,500	95%	3	Modernization, teleconsultations
Major urban areas	1,800	90%	4	Private care centers, public-private partnerships
Rural zones	400	60%	10	Mobile structures, telemedicine

The need to strengthen programs dedicated to territorial balance, notably through technological solutions proposed by Santech or MedTech Solutions, becomes a priority. Access to care must not be a discriminating factor depending on geographical location, to prevent the widening of social disparities.

Efforts to control expenses: measures and prospects within the framework of the PLFSS 2025

In response to this situation, the Social Security Financing Bill (PLFSS) for 2025 marks an important step in the attempt to rebalance expenses. Social security particularly envisions significant savings in the fields of medical biology and imaging, with cuts estimated at 3.9 billion euros next year and nearly 20 billion by 2030.

Prioritized measures include:

• ✂️ Limiting long-term sick leaves
• 🔍 Strengthened fight against redundant care
• 🚨 Targeted actions against reimbursement fraud
• 📉 Reform of overvalued tariffs
• 🤝 Mandatory signing of regulated agreements without negotiation margins

This orientation results in increased pressure on major players such as Bioscience, Radiology Plus, Auditech, and other groups operating in these domains. A dedicated report available on Aide BTS Assurance details the implications for professionals and patients. Reforms aim to establish a more balanced system, but resistance remains strong.

Measure ⚙️	Objective 🎯	Estimated Impact (Billion €) 💶	Main Concerned Sectors	Deadline ⏰
Limiting sick leaves	Reduce abuses and costs	1.2	Biology, Radiology
Fight against redundant care	Optimize care pathways	0.8	Biology
Tariff revisions	Reduce excessive margins	1.5	Radiology, Hearing aids
Regulated agreements	Align practices and costs	0.4	Biology

The role of technology and innovation in cost optimization

Technological advances are a key variable in balancing quality service and cost control. Companies such as MedTech Solutions, BioCare, and Santech innovate in the fields of diagnosis and prevention, contributing to a more efficient care pathway.

Recent examples include:

• 🔬 Connected solutions for biology enabling automated and real-time monitoring
• 🖥️ Cutting-edge imaging platforms for digital radiology
• 🎧 Smart hearing devices adapted to each patient profile
• 📈 Predictive analysis to limit redundant medical acts
• 🌐 Development of telemedicine and tele-diagnosis

This technological orientation is also a strategic lever in fighting financial misuse, improving traceability and transparency of medical acts. The integration of such innovations into public policy is explicitly supported by health sector strategic committees, as reported on the Ministry of Economy website.

Prospects for reform and calls for determined action

In a context where profitability in the sectors of biology, radiology, and hearing aids far exceeds the national average, the challenges of deep reform are apparent. The health insurance urges to deflate these “economic rents” to ensure a fair distribution of expenses and guarantee the system’s sustainability.

Proposed avenues include:

• 🔍 Strengthening financial and tariff controls
• 🤝 Encouraging balanced public-private partnerships
• 🌍 Enhancing territorial regulation to correct inequalities
• 📊 Increasing transparency on margins and profitability of actors
• 📜 New regulations strictly governing relationships between insurers and professionals

Faced with these issues, a call for determined action is made to all levels of the system, whether policymakers, economic actors, or healthcare professionals. The goal set for 2030 is clear: to control expenses while maintaining the quality and access to care. This structural challenge, analyzed on sites like Challenges.fr, is now central in public debate.

FAQ – Understanding the financial issues of healthcare in 2025

• ❓ Why is medical biology particularly lucrative?
  The market concentration around a few major groups and prices above actual costs partly explain this high profitability.
• ❓ How does radiology influence Social Security expenses?
  The high demand, salaries of specialists, and current tariffs generate significant costs, making this sector central to budget discussions.
• ❓ What are the consequences of financialization on care quality?
  Excessive financialization can lead to concentration of players, territorial inequality, and pressure on care quality due to purely financial logic.
• ❓ What measures are planned to limit excessive expenses?
  The PLFSS 2025 foresees savings through limiting long-term sick leaves, combating redundant care, fighting fraud, and revising overvalued tariffs.
• ❓ What role do technologies play in managing healthcare costs?
  They enable better efficiency, reduction of redundancies, and increased traceability, contributing to expense control.

Source: www.challenges.fr